403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
NHS expedites advanced skin cancer patients into groundbreaking DNA vaccine trial
(MENAFN) The National Health Service (NHS) announced Monday that patients in England with advanced skin cancer will soon be enrolled in a groundbreaking cancer vaccine trial.
The trial will test a needle-free DNA vaccine administered over a two-year period, designed to train the immune system to recognize, fight, and "remember" cancer cells, potentially preventing the disease from recurring, according to an NHS statement.
"This kind of innovation is nothing short of life-saving and I want to see more of these world-leading treatments being developed in the UK," said Prime Minister Keir Starmer.
The NHS is partnering with UK life sciences company Scancell to expand access to eligible patients across the country. The initiative is part of NHS England’s Cancer Vaccine Launch Pad, described as "a world-first program" aimed at fast-tracking patient participation in vaccine trials at local hospitals.
"The Launch Pad has already begun helping thousands of patients to access trials of a personalised vaccine against bowel cancer, with more than 350 patients fast-tracked for consideration, and has now expanded to include a trial for melanoma," the statement added.
Melanoma, the most dangerous form of skin cancer, is the fifth most common cancer in the UK, accounting for about 4% of all new cases, according to the NHS. Data from Cancer Research UK shows melanoma diagnoses rose by 33% between 2009 and 2019.
"Skin cancer can have a devastating impact, and we know that cancer vaccines have the potential to revolutionise cancer care for patients in this country and across the world – and to save more lives," said NHS National Cancer Director Peter Johnson.
Unlike personalized vaccines tailored to individual tumors, this new DNA vaccine is designed to enhance the immune system's ability to detect and target cancer cells, improving the effectiveness of immunotherapy.
"This will accelerate the discovery of transformative treatments and improve services for patients, driving growth across the country while making sure as many people as possible can benefit from cutting-edge treatments,” added Starmer.
The trial will test a needle-free DNA vaccine administered over a two-year period, designed to train the immune system to recognize, fight, and "remember" cancer cells, potentially preventing the disease from recurring, according to an NHS statement.
"This kind of innovation is nothing short of life-saving and I want to see more of these world-leading treatments being developed in the UK," said Prime Minister Keir Starmer.
The NHS is partnering with UK life sciences company Scancell to expand access to eligible patients across the country. The initiative is part of NHS England’s Cancer Vaccine Launch Pad, described as "a world-first program" aimed at fast-tracking patient participation in vaccine trials at local hospitals.
"The Launch Pad has already begun helping thousands of patients to access trials of a personalised vaccine against bowel cancer, with more than 350 patients fast-tracked for consideration, and has now expanded to include a trial for melanoma," the statement added.
Melanoma, the most dangerous form of skin cancer, is the fifth most common cancer in the UK, accounting for about 4% of all new cases, according to the NHS. Data from Cancer Research UK shows melanoma diagnoses rose by 33% between 2009 and 2019.
"Skin cancer can have a devastating impact, and we know that cancer vaccines have the potential to revolutionise cancer care for patients in this country and across the world – and to save more lives," said NHS National Cancer Director Peter Johnson.
Unlike personalized vaccines tailored to individual tumors, this new DNA vaccine is designed to enhance the immune system's ability to detect and target cancer cells, improving the effectiveness of immunotherapy.
"This will accelerate the discovery of transformative treatments and improve services for patients, driving growth across the country while making sure as many people as possible can benefit from cutting-edge treatments,” added Starmer.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
More Story
Comments
No comment